TROY expression is associated with pathological stage and poor prognosis in patients treated with radical cystectomy

Nomura, Megumi; Matsumoto, Kazumasa; Shimizu, Yuriko; Ikeda, Masaomi; Amano, Noriyuki; Nishi, Mayuko; Ryo, Akihide; Nagashio, Ryo; Sato, Yuichi

doi:10.3233/cbm-181911

Cited by 3 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We sliced 10% formalin‐fixed and paraffin‐embedded tissues and cell lines into 3 μm thick sections and stained them with hematoxylin and eosin. To evaluate GAL3 expression, these sections were additionally immunostained using the Bond‐MAX Automated Immunohistochemistry system and Bond Polymer Refine Detection Kit (DC 9800; Leica Biosystems) based on our previous study with minor modifications 19 . First, the sections were deparaffinized and pretreated with Bond Epitope Retrieval Solution 2 (Leica Biosystems) at 100°C for 20 min.…”

Section: Methodsmentioning

confidence: 99%

“…To evaluate GAL3 expression, these sections were additionally immunostained using the Bond-MAX Automated Immunohistochemistry system and Bond Polymer Refine Detection Kit (DC 9800; Leica Biosystems) based on our previous study with minor modifications. 19 First, the sections were deparaffinized and pretreated with Bond Epitope Retrieval Solution 2 (Leica Biosystems) at 100 C for 20 min. After washing, peroxidase blocking was performed for 10 min.…”

Section: Evaluation Of Immunohistochemical Stainmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Galectin‐3 (GAL3), a protein encoded by the LGALS3 gene, plays diverse roles in cancer initiation, progression, and drug resistance. Accordingly, high GAL3 expression in tumor cells is associated with poor prognosis in non‐small cell lung cancer (NSCLC). However, the prognostic impact of GAL3 expression on patients with resected NSCLC receiving platinum‐based adjuvant chemotherapy (AC) remains unclear. This study aimed to determine the prognostic significance of GAL3 expression in NSCLC patients receiving platinum‐based AC. Methods The study included 111 patients with completely resected stages II and IIIA NSCLC who were receiving platinum‐based AC. GAL3 expression in cancer cells was evaluated immunohistochemically according to H‐score (“histo score), with a score of ≥170 considered as high expression. The correlation of GAL3 expression with clinicopathological characteristics and survival was subsequently evaluated. Results In survival analysis, GAL3 expression was significantly associated with recurrence‐free survival (RFS) and overall survival (OS). In multivariate analysis, GAL3 expression was an independent predictive factor of RFS rather than OS. Conclusions GAL3 expression is a reliable biomarker to predict the prognosis of completely resected NSCLC patients receiving platinum‐based AC.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Evaluation Of Immunohistochemical Stainmentioning

confidence: 99%

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Formalin-fixed (10%) and paraffin-embedded tissues were processed into 3-μm-thick sections. Immunohistochemical staining was performed using a Leica Bond-Max automated system and the BOND polymer Refine Detection Kit (Leica Biosystems, Bannockburn, IL), based on the previous report of Nomura et al (26). Tissues were first deparaffinized with AutoDewaxer and antigens were retrieved with BOND Epitope Retrieval Solution 2 at 100°C for 20 min.…”

Section: Methodsmentioning

confidence: 99%

TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Platinum-based adjuvant chemotherapy after complete resection has become a standard treatment for patients with stage II to IIIA non-small cell lung cancer; however, not all patients exhibit survival benefits. Therefore, the development of predictive biomarkers for selecting a subgroup of patients who may show improved survival after these treatments is important. Among the 42 proteins identified here using a proteomics analysis that were recognized by autoantibodies in pretreated sera from patients with lung adenocarcinoma who received platinum-based adjuvant chemotherapy, the tumor necrosis factor-receptor-associated protein 1 (TRAP1) was detected in patients with a short disease-free survival. TRAP1 expression was immunohistochemically analyzed in 64 patients with completely resected stage II and IIIA lung adenocarcinoma treated with platinum-based adjuvant chemotherapy. TRAP1 expression was significantly associated with higher p-TNM stage (P = 0.005) and lymph node metastasis (P = 0.017). Moreover, TRAP1 expression was significantly correlated with a shorter disease-free survival (P = 0.028). Furthermore, TRAP1-siRNA-treated LC-2/ad cells derived from lung adenocarcinoma exhibited significantly reduced proliferation and increased sensitivity to cisplatin. These results suggest that TRAP1 expression is a valuable biomarker for predicting the poor survival of platinum-based adjuvant chemotherapy in patients with resected lung adenocarcinoma.

show abstract

High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy

Amano

Matsumoto

Shimizu

et al. 2021

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

TROY expression is associated with pathological stage and poor prognosis in patients treated with radical cystectomy

Cited by 3 publications

References 26 publications

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy

TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma

High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy

Contact Info

Product

Resources

About